- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05156281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
Рандомизированное, двойное слепое, двойное фиктивное исследование в параллельных группах, сравнивающее эффективность и безопасность ремибрутиниба по сравнению с терифлуномидом у участников с рецидивирующим рассеянным склерозом с последующим длительным лечением открытым ремибрутинибом
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Buenos Aires, Аргентина, C1012AAR
- Novartis Investigative Site
-
CABA, Аргентина, C1181ACH
- Novartis Investigative Site
-
Córdoba, Аргентина, X5004CDT
- Novartis Investigative Site
-
-
Mendoza Province
-
Bombal, Mendoza Province, Аргентина, M5500DXO
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, S2000BZL
- Novartis Investigative Site
-
Rosario, Santa Fe Province, Аргентина, S2000DSW
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel de, Tucumán Province, Аргентина, T4000
- Novartis Investigative Site
-
-
-
-
-
Plovdiv, Болгария, 4002
- Novartis Investigative Site
-
Sofia, Болгария, 1309
- Novartis Investigative Site
-
Sofia, Болгария, 1431
- Novartis Investigative Site
-
Sofia, Болгария, 1407
- Novartis Investigative Site
-
-
-
-
-
São Paulo, Бразилия, 01240-020
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Бразилия, 29055-450
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Бразилия, 70200-730
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Бразилия, 81210-310
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90430-001
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90560-032
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90620-130
- Novartis Investigative Site
-
-
Santa Catarina
-
Joinville, Santa Catarina, Бразилия, 89202-165
- Novartis Investigative Site
-
-
-
-
-
Essen, Германия, 45147
- Novartis Investigative Site
-
Hamburg, Германия, 22179
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Германия, 79106
- Novartis Investigative Site
-
-
-
-
-
Athens, Греция, 115 28
- Novartis Investigative Site
-
Athens, Греция, 115 26
- Novartis Investigative Site
-
Chaïdári, Греция, 124 62
- Novartis Investigative Site
-
Ioannina, Греция, 455 00
- Novartis Investigative Site
-
Larissa, Греция, 411 10
- Novartis Investigative Site
-
Thessaloniki, Греция, 532 46
- Novartis Investigative Site
-
Thessaloniki, Греция, 546 36
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kochi, Kerala, Индия, 682025
- Novartis Investigative Site
-
-
Maharashtra
-
Pune, Maharashtra, Индия, 411013
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Индия, 110060
- Novartis Investigative Site
-
-
Punjab
-
Amritsar, Punjab, Индия, 143006
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Индия, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Индия, 226007
- Novartis Investigative Site
-
-
West Bengal
-
Kolkata, West Bengal, Индия, 700017
- Novartis Investigative Site
-
-
-
-
-
Lleida, Испания, 25198
- Novartis Investigative Site
-
Madrid, Испания, 28040
- Novartis Investigative Site
-
Madrid, Испания, 28009
- Novartis Investigative Site
-
Málaga, Испания, 29016
- Novartis Investigative Site
-
Seville, Испания, 41009
- Novartis Investigative Site
-
Valencia, Испания, 46026
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Испания, 15706
- Novartis Investigative Site
-
-
Araba
-
Vitoria-Gasteiz, Araba, Испания, 01009
- Novartis Investigative Site
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Испания, 08907
- Novartis Investigative Site
-
-
Castille-La Mancha
-
Albacete, Castille-La Mancha, Испания, 02006
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Испания, 08003
- Novartis Investigative Site
-
-
La Rioja
-
Logroño, La Rioja, Испания, 26006
- Novartis Investigative Site
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Испания, 28223
- Novartis Investigative Site
-
Torrejón de Ardoz, Madrid, Испания, 28850
- Novartis Investigative Site
-
-
Principality of Asturias
-
Gijón, Principality of Asturias, Испания, 33394
- Novartis Investigative Site
-
-
Valencia
-
Valencia, Valencia, Испания, 46017
- Novartis Investigative Site
-
-
-
-
-
Naples, Италия, 80138
- Novartis Investigative Site
-
-
BR
-
Brindisi, BR, Италия, 72100
- Novartis Investigative Site
-
-
FG
-
Foggia, FG, Италия, 71122
- Novartis Investigative Site
-
-
IS
-
Pozzilli, IS, Италия, 86077
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Италия, 98124
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Италия, 41126
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Италия, 27100
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Италия, 10043
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Канада, T6G 2B7
- Novartis Investigative Site
-
-
British Columbia
-
Burnaby, British Columbia, Канада, V5G 2X6
- Novartis Investigative Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Канада, B3H 4K4
- Novartis Investigative Site
-
-
Ontario
-
Ottawa, Ontario, Канада, K1H 8L6
- Novartis Investigative Site
-
-
Quebec
-
Lévis, Quebec, Канада, G6W 0M5
- Novartis Investigative Site
-
Montreal, Quebec, Канада, H4A 3T2
- Novartis Investigative Site
-
Québec, Quebec, Канада, G1J 1Z4
- Novartis Investigative Site
-
Saint-Jérôme, Quebec, Канада, J7Z 5T3
- Novartis Investigative Site
-
-
-
-
-
Beijing, Китай, 100034
- Novartis Investigative Site
-
Shanghai, Китай, 200025
- Novartis Investigative Site
-
Shanghai, Китай, 200040
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Китай, 430030
- Novartis Investigative Site
-
Wuhan, Hubei, Китай, 430060
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210029
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Китай, 750004
- Novartis Investigative Site
-
-
Shanxi
-
Taiyuan, Shanxi, Китай, 030001
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, Китай, 310016
- Novartis Investigative Site
-
Hangzhou, Zhejiang, Китай, 310006
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Китай, 325000
- Novartis Investigative Site
-
-
-
-
-
Mexico City, Мексика, 14050
- Novartis Investigative Site
-
Querétaro, Мексика, 76070
- Novartis Investigative Site
-
-
Chihuahua
-
Chihuahua City, Chihuahua, Мексика, 31203
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Мексика, 06700
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Польша, 15-704
- Novartis Investigative Site
-
Glogow Wielkopolski, Польша, 36-060
- Novartis Investigative Site
-
Katowice, Польша, 40-081
- Novartis Investigative Site
-
Katowice, Польша, 40-571
- Novartis Investigative Site
-
Katowice, Польша, 40-686
- Novartis Investigative Site
-
Katowice, Польша, 40-689
- Novartis Investigative Site
-
Lublin, Польша, 20-701
- Novartis Investigative Site
-
Wroclaw, Польша, 51-685
- Novartis Investigative Site
-
Zabrze, Польша, 41-800
- Novartis Investigative Site
-
-
Poznan
-
Plewiska, Poznan, Польша, 62-064
- Novartis Investigative Site
-
-
-
-
-
Braga, Португалия, 4710-243
- Novartis Investigative Site
-
Coimbra, Португалия, 3004-561
- Novartis Investigative Site
-
Leiria, Португалия, 2410-197
- Novartis Investigative Site
-
Lisbon, Португалия, 1649-035
- Novartis Investigative Site
-
Lisbon, Португалия, 1169-050
- Novartis Investigative Site
-
Matosinhos Municipality, Португалия, 4454-513
- Novartis Investigative Site
-
Santa Maria da Feira, Португалия, 4520-211
- Novartis Investigative Site
-
-
-
-
-
Guaynabo, Пуэрто-Рико, 00968
- Caribbean Center for Clinical Research Inc
-
-
-
-
-
Campulung Muscel, Румыния, 115100
- Novartis Investigative Site
-
Constanța, Румыния, 900591
- Novartis Investigative Site
-
-
ROM
-
Brasov, ROM, Румыния, 500123
- Novartis Investigative Site
-
Constanța, ROM, Румыния, 900123
- Novartis Investigative Site
-
-
-
-
-
Banská Bystrica, Словакия, 975 17
- Novartis Investigative Site
-
Banská Bystrica, Словакия, 974 04
- Novartis Investigative Site
-
Bratislava, Словакия, 833 05
- Novartis Investigative Site
-
-
-
-
-
Celje, Словения, 3000
- Novartis Investigative Site
-
Ljubljana, Словения, 1000
- Novartis Investigative Site
-
-
Slovenia
-
Maribor, Slovenia, Словения, 2000
- Novartis Investigative Site
-
-
-
-
Invernesshire
-
Inverness, Invernesshire, Соединенное Королевство, IV2 3RE
- Novartis Investigative Site
-
-
Kent
-
Canterbury, Kent, Соединенное Королевство, CT1 3NG
- Novartis Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85018
- Ctr for Neurology and Spine
-
-
California
-
Hanford, California, Соединенные Штаты, 93230
- Vladimir Royter MD APMC
-
Los Angeles, California, Соединенные Штаты, 90073
- VA Greater LA Healthcare System
-
West Hollywood, California, Соединенные Штаты, 90048
- Regina Berkovich MD PhD Inc
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- CU Anschutz Med Campus
-
Denver, Colorado, Соединенные Штаты, 80210
- Colorado Neurological Research PC
-
-
Connecticut
-
Stamford, Connecticut, Соединенные Штаты, 06905
- New England Institute for Clinical Research
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20007
- Georgetown University Hospital
-
Washington D.C., District of Columbia, Соединенные Штаты, 20007
- Georgetown University Hospital Research
-
-
Florida
-
Bradenton, Florida, Соединенные Штаты, 34209
- Nova Clinical Research LLC
-
Gainesville, Florida, Соединенные Штаты, 32610
- University of Florida
-
Hollywood, Florida, Соединенные Штаты, 33021
- Memorial Healthcare System
-
Maitland, Florida, Соединенные Штаты, 32751
- Neurology Associates PA
-
Miami, Florida, Соединенные Штаты, 33136
- UM Department Of Neurology
-
Miami, Florida, Соединенные Штаты, 33133
- Gables Neurology
-
Naples, Florida, Соединенные Штаты, 34105
- Aqualane Clinical Research
-
Orlando, Florida, Соединенные Штаты, 32803
- Advent Health Orlando
-
Pembroke Pines, Florida, Соединенные Штаты, 33024
- Humanity Clinical Research
-
Pensacola, Florida, Соединенные Штаты, 32514
- Emerald Coast Neurology
-
Port Orange, Florida, Соединенные Штаты, 32127
- Brain and Spine Institute
-
Vero Beach, Florida, Соединенные Штаты, 32960
- Vero Beach Neurology
-
Winter Park, Florida, Соединенные Штаты, 32789
- Conquest Research
-
-
Indiana
-
Merrillville, Indiana, Соединенные Штаты, 46410
- Methodist Neuroscience Institute
-
-
Kansas
-
Kansas City, Kansas, Соединенные Штаты, 66160
- University of Kansas Hospital
-
-
Kentucky
-
Nicholasville, Kentucky, Соединенные Штаты, 40356
- Baptist Physicians Lexington
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Frederick, Maryland, Соединенные Штаты, 21702
- Clinre Comprehensive Neurology
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02111
- Tufts Medical Center
-
-
Missouri
-
Kansas City, Missouri, Соединенные Штаты, 64128
- Kansas City VA Medical Center
-
-
New York
-
Patchogue, New York, Соединенные Штаты, 11772
- South Shore Neurologic Associates
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599-9500
- University Of NC At Chapel Hill
-
Charlotte, North Carolina, Соединенные Штаты, 28210
- Piedmont HealthCare
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43235
- The Boster Ctr for MS
-
Dayton, Ohio, Соединенные Штаты, 45408
- Neurology Diagnostics Inc
-
-
Pennsylvania
-
Hershey, Pennsylvania, Соединенные Штаты, 17033
- Penn State Hershey Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Соединенные Штаты, 29605
- Premier Neurology
-
Old Point Station, South Carolina, Соединенные Штаты, 29707
- Metrolina Neurological Associates PA
-
-
Tennessee
-
Knoxville, Tennessee, Соединенные Штаты, 37922
- Sibyl Wray MD Neurology PC
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75231
- Carum Research
-
El Paso, Texas, Соединенные Штаты, 79935
- Med Research Inc
-
Frisco, Texas, Соединенные Штаты, 75035
- Lone Star Neurology
-
San Antonio, Texas, Соединенные Штаты, 78258
- Lonestar Neurology of San Antonio
-
San Antonio, Texas, Соединенные Штаты, 78229
- UT Health MARC Medical Arts and Research Center
-
Sherman, Texas, Соединенные Штаты, 75092
- Texas Institute for Neurological Disorders
-
Temple, Texas, Соединенные Штаты, 76508
- Baylor Scott and White
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98101
- Virginia Mason Medical Centre
-
Seattle, Washington, Соединенные Штаты, 98133
- University of Washington MS Clinic
-
-
West Virginia
-
Crab Orchard, West Virginia, Соединенные Штаты, 25827
- Elligo Health Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53215
- Ascension St Francis Center
-
-
-
-
-
Konya, Турция (Туркие), 42130
- Novartis Investigative Site
-
-
Atakum
-
Samsun, Atakum, Турция (Туркие), 55200
- Novartis Investigative Site
-
-
Balcova
-
Izmir, Balcova, Турция (Туркие), 35340
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Турция (Туркие), 34098
- Novartis Investigative Site
-
Istanbul, Fatih, Турция (Туркие), 34093
- Novartis Investigative Site
-
-
Karabaglar
-
Izmir, Karabaglar, Турция (Туркие), 35150
- Novartis Investigative Site
-
-
Kocaeli
-
Köseköy, Kocaeli, Турция (Туркие), 41380
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Турция (Туркие), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Турция (Туркие), 16140
- Novartis Investigative Site
-
-
Pendik
-
Istanbul, Pendik, Турция (Туркие), 34899
- Novartis Investigative Site
-
-
Sancaktepe
-
Istanbul, Sancaktepe, Турция (Туркие), 34785
- Novartis Investigative Site
-
-
-
-
-
Caen, Франция, 14033
- Novartis Investigative Site
-
Clermont-Ferrand, Франция, 63003
- Novartis Investigative Site
-
Dijon, Франция, 21000
- Novartis Investigative Site
-
Gonesse, Франция, 95500
- Novartis Investigative Site
-
Grenoble, Франция, 38043
- Novartis Investigative Site
-
Lille, Франция, 59037
- Novartis Investigative Site
-
Lille, Франция, 59000
- Novartis Investigative Site
-
Nice, Франция, 06000
- Novartis Investigative Site
-
Nîmes, Франция, 30029
- Novartis Investigative Site
-
Poissy, Франция, 78303
- Novartis Investigative Site
-
Toulouse, Франция, 31059
- Novartis Investigative Site
-
-
Haute Vienne
-
Limoges, Haute Vienne, Франция, 87000
- Novartis Investigative Site
-
-
Val De Marne
-
Toulon, Val De Marne, Франция, 83800
- Novartis Investigative Site
-
-
-
-
-
Zagreb, Хорватия, 10000
- Novartis Investigative Site
-
-
Croatia
-
Zagreb, Croatia, Хорватия, 10000
- Novartis Investigative Site
-
-
HRV
-
Split, HRV, Хорватия, 21000
- Novartis Investigative Site
-
Varaždin, HRV, Хорватия, 42000
- Novartis Investigative Site
-
-
Vukovar
-
Vukovar, Vukovar, Хорватия, 32000
- Novartis Investigative Site
-
-
-
-
-
Brno, Чехия, 602 00
- Novartis Investigative Site
-
Hradec Králové, Чехия, 500 05
- Novartis Investigative Site
-
Teplice, Чехия, 415 29
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Швеция, 102 35
- Novartis Investigative Site
-
-
-
-
-
Tallinn, Эстония, 11315
- Novartis Investigative Site
-
Tartu, Эстония, 50406
- Novartis Investigative Site
-
-
-
-
-
Pretoria, Южная Африка, 0041
- Novartis Investigative Site
-
Rosebank, Южная Африка, 2196
- Novartis Investigative Site
-
-
Free State
-
Bloemfontein, Free State, Южная Африка, 9301
- Novartis Investigative Site
-
-
-
-
-
Fukuoka, Япония, 8128582
- Novartis Investigative Site
-
Niigata, Япония, 9518520
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 4668560
- Novartis Investigative Site
-
-
Chiba
-
Chiba, Chiba, Япония, 2608677
- Novartis Investigative Site
-
Ichihara, Chiba, Япония, 2990111
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Япония, 8100022
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 0630005
- Novartis Investigative Site
-
-
Hyōgo
-
Kobe, Hyōgo, Япония, 6500017
- Novartis Investigative Site
-
Nishinomiya, Hyōgo, Япония, 663 8501
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara, Kanagawa, Япония, 2591193
- Novartis Investigative Site
-
Sagamihara, Kanagawa, Япония, 2520375
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto, Kyoto, Япония, 6168255
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Япония, 9838512
- Novartis Investigative Site
-
-
Nara
-
Kashihara, Nara, Япония, 6348522
- Novartis Investigative Site
-
-
Osaka
-
Moriguchi, Osaka, Япония, 5708507
- Novartis Investigative Site
-
Suita, Osaka, Япония, 5650871
- Novartis Investigative Site
-
-
Saitama
-
Higashi-Matsuyama, Saitama, Япония, 3550005
- Novartis Investigative Site
-
-
Tokyo
-
Kodaira, Tokyo, Япония, 1878551
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Япония, 1628666
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Япония, 1600023
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Япония, 1608582
- Novartis Investigative Site
-
tabashi City, Tokyo, Япония, 1738610
- Novartis Investigative Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- 18 to 55 years of age
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
- EDSS score of 0 to 5.5 (inclusive)
- Neurologically stable within 1 month
Exclusion Criteria:
-
Diagnosis of primary progressive multiple sclerosis (PPMS)
-
Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
-
History of clinically significant CNS disease other than MS
-
Ongoing substance abuse (drug or alcohol)
-
History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
-
Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
-
suicidal ideation or behavior
-
Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
-
Participants who have had a splenectomy
-
Active clinically significant systemic bacterial, viral, parasitic or fungal infections
-
Positive results for syphilis or tuberculosis testing
-
Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
-
Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
-
Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
-
History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.
-
History of severe renal disease or creatinine level
-
Participants at risk of developing or having reactivation of hepatitis
-
Hematology parameters at screening:
- Hemoglobin: < 10 g/dl (<100g/L)
- Platelets: < 100000/mm3 (<100 x 109/L)
- Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
- White blood cells: <3 000/mm3 (<3.0 x 109/L)
- Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
- B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
-
History or current diagnosis of significant ECG abnormalities
-
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
-
Use of other investigational drugs
-
Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
-
History of gastrointestinal bleeding
-
Major surgery within 8 weeks prior to screening
-
History of hypersensitivity to any of the study drugs or excipients
-
Pregnant or nursing (lactating) female participants, prior to randomization
-
Women of childbearing potential not using highly effective contraception
-
Sexually active males not agreeing to use condom
-
Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
-
Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization
Inclusion to Extension part:
• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)
Other inclusion and exclusion criteria may apply.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Remibrutinib - Core
Remibrutinib tablet and matching placebo of teriflunomide capsule |
tablet taken orally
Другие имена:
|
|
Активный компаратор: Teriflunomide - Core
Teriflunomide capsule and matching placebo remibrutinib tablet |
capsule taken orally |
|
Экспериментальный: Remibrutinib - Extension
Participants on remibrutinib in Core will continue on remibrutinib tablet |
tablet taken orally
Другие имена:
|
|
Экспериментальный: Remibrutinib - Extension (on teriflunomide in Core)
Participants on teriflunomide in Core will switch to remibrutinib tablet |
tablet taken orally
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Временное ограничение: From Baseline, up to 30 months
|
ARR is the average number of confirmed MS relapses in a year |
From Baseline, up to 30 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Annualized rate of new or enlarging T2 lesion [Core Part]
Временное ограничение: Baseline up to 30 months
|
Number of new/newly enlarged T2 lesions per year |
Baseline up to 30 months
|
|
Neurofilament light chain (Nfl) [Core Part]
Временное ограничение: Baseline up to 30 months
|
Neurofilament light chain (NfL) concentration in serum |
Baseline up to 30 months
|
|
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Временное ограничение: Baseline up to 30 months
|
Average number of Gd-enhancing T1 lesions per scan |
Baseline up to 30 months
|
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI |
Baseline up to 30 months
|
|
Time to first confirmed relapse [Core Part]
Временное ограничение: Baseline up to 30 months
|
Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating. |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve |
Baseline up to 30 months
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Baseline up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Временное ограничение: Baseline, up to 30 months
|
The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score |
Baseline, up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand) |
Baseline up to 30 months
|
|
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Временное ограничение: Baseline up to 30 months
|
The composite involves CDP and worsening by at least 20% in T25FW and 9HPT |
Baseline up to 30 months
|
|
Change from Baseline in T2 lesion volume [Core Part]
Временное ограничение: Baseline up to 30 months
|
Change from baseline in total T2 lesion volume. |
Baseline up to 30 months
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Временное ограничение: Baseline up to 30 months
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Baseline up to 30 months
|
|
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Временное ограничение: Baseline up to 30 months
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Baseline up to 30 months
|
|
Pharmacokinetics of remibrutinib [Core Part]
Временное ограничение: Month 1, Month 6
|
Blood concentrations of remibrutinib |
Month 1, Month 6
|
|
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Day 1 Extension up to 5 years
|
|
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
ARR is the average number of confirmed MS relapses in a year |
Day 1 Extension up to 5 years
|
|
Annualized rate of new or enlarging T2 lesion [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
Number of new/newly enlarged T2 lesions per year |
Day 1 Extension up to 5 years
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Day 1 Extension up to 5 years
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Day 1 Extension up to 5 years
|
|
Neurofilament light chain (NfL) [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
Neurofilament light chain (NfL) concentration in serum |
Day 1 Extension up to 5 years
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Временное ограничение: Day 1 Extension up to 5 years
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Day 1 Extension up to 5 years
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CLOU064C12302
- 2023-509372-41-00 (Идентификатор реестра: EU CTIS)
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .